Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SHR0302 in healthy volunteers
NCT02423538Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Apr 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ivarmacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Hengrui. Primary endpoints: Adverse events and the number of volunteers with adverse events, Maximum plasma concentration and 3 more. Status: unknown.
02
Drugs
ivarmacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02423538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02423538.